This Won’t Make The News

A new article was just published in Frontiers in Pharmacology: “Association between statin therapy and dementia risk: evidence from All of Us and UK Biobank with coenzyme Q7-related mediation analysis.”

I make this very simple. I am just copy-pasting the important parts of the paper with some minimal explanation.

Introduction:

“a population-based retrospective cohort study using the All of Us Research Program (discovery cohort, n = 83,355; 31,513 statin users) and UK Biobank (replication cohort, n = 173,282; 43,976 statin users). Participants were adults aged ≥40 years who self-identified as White, followed from 2006 through 2023 (discovery) and 2017 (replication). Inverse probability of treatment weighting balanced baseline characteristics. Dementia risk was estimated using Cox proportional hazards models. An exploratory mediation analysis examined low-density lipoprotein cholesterol (LDL-C) and coenzyme Q7, a protein involved in CoQ10 biosynthesis, as potential pathways linking statin use and dementia.”

Meaning:

They evaluated data for thousands of people for 17 years, looking at how many of them developed dementia among those taking statins and those not taking statins.

Results:

“Statin use was associated with significantly increased dementia risk in both cohorts (discovery: adjusted HR 2.22, 95% CI 2.02–2.44; replication: adjusted HR 2.54, 95% CI 1.98–3.33). Clear intensity-dependent relationships were observed, with high-intensity statins conferring 14% greater risk than moderate-to-low intensity therapy. In the exploratory mediation analysis, the estimated indirect effect through coenzyme Q7 was statistically significant and accounted for 8.2% of the total association, whereas the indirect effect through LDL-C was not statistically significant.”

Meaning:

Statins causing dementia had a hazard ratio (HR) of 2.22 and, with replication, an even larger HR of 2.54; both were significant (HR>=2), which warrants further evaluation to assess causation. However, when they looked at the association between LDL and dementia, there was no correlation.

Conclusion:

“Statin use was associated with higher dementia risk in both cohorts, and exploratory mediation findings suggested a modest statistical indirect association through COQ7, which should be considered hypothesis-generating. Given the observational design and conflicting evidence in the literature, these findings warrant further investigation before informing clinical decisions about statin therapy.”

Checked for CoQ7 levels (a marker for CoQ10):

(Coenzyme 7 was measurable in the blood because it is a good proxy for CoQ10. When people take statins, it blocks CoQ10 synthesis.)

“Higher COQ7 levels were significantly associated with lower odds of dementia (OR: 0.851, 95% CI: 0.744–0.973; P = 0.018), whereas LDL-C levels were not significantly associated with dementia (OR: 0.955, 95% CI: 0.832–1.095; P = 0.509). Restricted cubic spline analysis showed an overall association between COQ7 levels and dementia (P = 0.009), with evidence of nonlinearity (P = 0.044). Lower COQ7 levels were associated with higher odds of dementia relative to the median, with a flattening of the curve above the median. No significant overall association or nonlinearity was observed for LDL-C (P for overall association = 0.700; P for nonlinearity = 0.887)”.

Meaning:

Since statins reduce CoQ10, thereby CoQ7, they could show via blood that statin use increased dementia but having higher levels of CoQ7 (thereby 10), was beneficial. Here you need to look at the P value. Depending on what they set as their target level, they found P = 0.018 significant (usually P =< 0.05 is significant), and they found LDL-C not significant at P = 0.509; in another test for nonlinearity, they found an even weaker P = 0.887.

My summary:

  1. Don’t worry about higher LDL. It’s not harming you.
  2. Don’t take statins. Statins are harmful to your health.

There you have it.

Comments are welcome, as always, and are moderated for appropriateness.

Angela

Unknown's avatar

About Angela A Stanton, Ph.D.

Angela A Stanton, PhD, is a Neuroeconomist focusing on chronic pain--migraine in particular--physiology, electrolyte homeostasis, nutrition, and genetics. She lives in Southern California. Her current research is focused on migraine cause, prevention, and treatment without the use of medicine. As a forever migraineur from childhood, her discovery was helped by experimenting on herself. She found the cause of migraine to be at the ionic level, associated with disruption of the electrolyte homeostasis, resulting from genetic variations of all voltage dependent channels, gates, and pumps (chanelopathy) that modulate electrolyte mineral density and voltage in the brain. In addition, insulin and glucose transporters, and several other variants, such as MTHFR variants of B vitamin methylation process and many others are different in the case of a migraineur from the general population. Migraineurs are glucose sensitive (carbohydrate intolerant) and should avoid eating carbs as much as possible. She is working on her hypothesis that migraine is a metabolic disease. As a result of the success of the first edition of her book and her helping over 5000 migraineurs successfully prevent their migraines world wide, all ages and both genders, and all types of migraines, she published the 2nd (extended) edition of her migraine book "Fighting The Migraine Epidemic: Complete Guide: How To Treat & Prevent Migraines Without Medications". The 2nd edition is the “holy grail” of migraine cause, development, and prevention, incorporating all there is to know. It includes a long section for medical and research professionals. The book is full of academic citations (over 800) to authenticate the statements she makes to make it easy to follow up by those interested and to spark further research interest. It is a "Complete Guide", published on September 29, 2017. Dr. Stanton received her BSc at UCLA in Mathematics, MBA at UCR, MS in Management Science and Engineering at Stanford University, PhD in Economics with dissertation in neuroscience (culminating in Neuroeconomics) at Claremont Graduate University, fMRI certification at Harvard University Medical School at the Martinos Center for Neuroimaging for experimenting with neurotransmitters on human volunteers, certification in LCHF/ketogenic diet from NN (Nutrition Network), certification in physiology (UPEN via Coursea), Nutrition (Harvard Shool of Public Health) and functional medicine studies. Dr. Stanton is an avid sports fan, currently power weight lifting and kickboxing. For relaxation (yeah.. about a half minute each day), she paints and photographs and loves to spend time with her family of husband of 45 years, 2 sons and their wives, and 2 granddaughters. Follow her on Twitter at: @MigraineBook, LinkedIn at https://www.linkedin.com/in/angelaastantonphd/ and facebook at https://www.facebook.com/DrAngelaAStanton/
This entry was posted in Big Pharma, cholesterol, Healthcare, Must Read, statins and tagged , , , , , , , , . Bookmark the permalink.

I would love to see your thoughts!

This site uses Akismet to reduce spam. Learn how your comment data is processed.